ALLOVIR INC (ALVR)
US0198181036 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
ALVR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023
ALVR stock results show that AlloVir missed analyst estimates for earnings per share the fourth quarter of 2023.
ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AlloVir (NASDAQ:ALVR) just reported results for the fourth quarter of 2023.Allo...
ALVR DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 17, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 16, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit....
ALVR DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the AlloVir, Inc. (ALVR) Class Action - Nationally Ranked Investors Rights Firm Encourages Investors With Significant Losses to Contact the Firm
ATLANTA, GA - (NewMediaWire) - March 14, 2024 - Holzer & Holzer, LLC reminds shareholders that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and prospects, including allegations that: (i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that the Company would ultimately discontinue the posoleucel Phase 3 studies; (iii) accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Holzer & Holzer, LLC Reminds Shareholders of the March 19, 2024 Lead Plaintiff Deadline in the AlloVir, Inc. (ALVR) Class Action - Nationally Ranked Investors Rights Firm Encourages Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
ALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022...
ALVR DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit....
ALVR IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ALVR IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 10, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ROSEN, NATIONAL TRIAL COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 08, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ROSEN, NATIONAL TRIAL COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
WHY: NEW YORK, NY - (NewMediaWire) - March 07, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline
Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit....
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the...